Evidence-based Critical Evaluation of Glycemic Potential of Cynodon dactylon

Santosh Kumar Singh, Prashant Kumar Rai, Dolly Jaiswal and Geeta Watal

Alternative Therapeutics Unit, Drug Development Division, Medicinal Research Lab, Department of Chemistry, University of Allahabad, Allahabad 211 002, India

The present study is an extension of our previous work carried out on Cynodon dactylon. This study deals with the critical evaluation of glycemic potential of ethanolic extract of defatted C. dactylon. The doses of 250, 500 and 750 mg kg\(^{-1}\) bw of the extract were administered orally to normal as well as Streptozotocin-induced diabetic rats to study its glycemic potential. The effect of repeated oral administration of the same doses of ethanolic extract was also studied on serum lipid profile of severely diabetic (SD) rats. The dose of 500 mg kg\(^{-1}\) bw was identified as the most effective dose as it lowered the blood glucose levels of normal by 42.12\% and of diabetic by 43.42\% during fasting blood glucose (FBG) and glucose tolerance test respectively. The SD rats were also treated daily with this identified dose of 500 mg kg\(^{-1}\) bw for 2 weeks and a significant reduction of 56.34\% was observed in FBG level. Total cholesterol, low density lipoprotein and triglyceride levels were also decreased by 32.94, 64.06 and 48.46\% respectively in SD rats whereas, cardioprotective high density lipoprotein increased by 16.45\%. The reduced urine sugar level and increased body weight are additional advantages. These evidences clearly indicate that the ethanolic extract of defatted C. dactylon has high antidiabetic potential along with good hypolipidemic profile.

Keywords: antidiabetic – Cynodon dactylon – hypolipidemic – poaceae – streptozotocin

Introduction

Diabetes, a global burden, is characterized by fast elevation of blood sugar level. The incidence of diabetes mellitus is rising all over the world, especially in Asia. Many oral hypoglycemic agents, such as biguanides and sulfonylurea are available along with insulin for the treatment of diabetes mellitus but they have significant side effects (1,2) and sometimes they are found to be ineffective in chronic diabetic patients (3). Thus, there is an increasing demand of natural and synthetic products with high antidiabetic potential and lesser side effects (4). The researches conducted over the last several decades have shown that plant and plant-based therapies have high potential to treat and control diabetes (5–7) and its complications (8). Therefore, search for safe and more effective agents has continued to be an important area of active research. Since ancient times, diabetes has been treated orally with several medicinal plants or their extracts, based on folklore medicine. These herbal remedies are apparently effective, produce minimal or no side effects and are of relative low costs as compared to oral synthetic hypoglycemic agents. Furthermore, after the recommendation made by WHO on diabetes mellitus, investigation of hypoglycemic agents from medicinal plants have become more important (9–11).

Cynodon dactylon (Fam: Poaceae) is commonly known as ‘Doob’ in India. It is a weed and has been regarded to possess varied medicinal properties. It has been used to treat urinary tract infection, calculi and prostatitis. The plant possesses antimicrobial and antiviral activity (12). The aqueous fluid extract of the rhizome is used as anti-inflammatory, diuretic, anti-emetic, purifying agent and...
also in dysentery (13,14). The plant extract also has significant application in dropsy and secondary syphilis (15). The plant is traditionally used as an agent to control diabetes in India (16,17). The present investigation was therefore carried out to evaluate the traditional use of *C. dactylon* scientifically. Since the aqueous extract of *C. dactylon* was found to have high antidiabetic potential (18), the study of its ethanolic extract was therefore undertaken to exploit further its antidiabetic potential in Streptozotocin (STZ)-induced diabetic rats.

**Methods**

**Preparation of Ethanolic Extract**

*Cynodon dactylon* was collected from the campus of University of Allahabad, Allahabad, India. It was identified and authenticated by Botanical Survey of India, Allahabad branch and Prof. B.D. Singh, taxonomist, Allahabad Agriculture Institute, Naini, Allahabad. A voucher specimen (AA518) has been submitted. The whole green plant was washed with water and shade-dried. About 500 g of shade-dried plant was treated with hexane (2\(\times\)2.5 l) to defat it and then extracted with ethanol (3 l) for 48 h. The resulting extract was filtered and concentrated in rotavapor under reduced pressure to give a residue (yield about 10.8% w/w) for further exploration.

**Experimental Animals**

Male albino wistar rats of same age group and body weight 150–200 g were selected for all the experiments. Animals obtained from National Institute of Communicable Disease (NICD), New Delhi, India, were housed in polypropylene cages at an ambient temperature of 25–30°C and 45–55% relative humidity with a 12 h each of dark and light cycle. Rats were fed pellet diet (Golden feed, New Delhi India) and water *ad libitum*. The study was approved by the Institutional Ethical Committee (83 a/a/04/CPCSEA).

**Induction of Diabetes in Rats**

Diabetes was induced by a single intraperitoneal injection of freshly prepared STZ (50 mg kg\(^{-1}\) bw) in 0.1 M citrate buffer (pH = 4.5) to overnight fasted rats. After 3 days of STZ administration, rats with marked hyperglycemia (fasting blood glucose (FBZ) > 150 mg dl\(^{-1}\)) were selected for the study. The rats with hyperglycemia were divided into two groups.

- Mild diabetic (MD) rats with FBG 120–250 mg dl\(^{-1}\).
- Severely diabetic (SD) rats showing FBG above 250 mg dl\(^{-1}\).

**Estimation**

Blood glucose level (BGL), total cholesterol (TC), high density lipoprotein (HDL) cholesterol and triglycerides (TG) levels were estimated using standard kits of Bayer diagnostics, India. Low density lipoprotein (LDL) and very low density lipoprotein (VLDL) cholesterol levels were calculated from the above measurement by using Friedwald formula (19). Urine sugar was detected by reagent-based Uristix from Bayer Diagnostics.

\[
\text{VLDL} = \frac{\text{TG}}{5} \\
\text{LDL} = \frac{\text{TC}}{\left(\text{HDL} + \frac{\text{TG}}{5}\right)}
\]

**Experimental Design**

**Evaluation of Glycemic Management in Normal Healthy Rats**

Twenty-four normal healthy male rats were fasted overnight and divided equally into four groups of six rats each. Pretreatment FBG levels of each group were estimated. Group I served as untreated control given vehicle (water only) whereas, other three groups II, III and IV were given the powder of concentrated ethanolic extract suspended in distilled water (DW) orally in doses of 250, 500 and 750 mg kg\(^{-1}\) bw respectively. Blood samples were collected from the tail vein after 2, 4 and 6 h and percentage of hypoglycemia variations were calculated for each group.

**Glycemic Potential Assessment by Glucose Tolerance in MD Rats**

The hypoglycemic effect of ethanolic extract was evaluated in MD rats by glucose tolerance test. The overnight fasted rats were divided into four groups V, VI, VII and VIII of six rats each. Pretreatment FBG levels of each group were estimated. Group V (Diabetic control) received vehicle (water only) whereas, variable doses of 250, 500 and 750 mg kg\(^{-1}\) bw of ethanolic extract were given orally to groups VI, VII and VIII respectively. BGL of each group was further estimated after 90 min of the treatment considered as 0 h value. About 2 g kg\(^{-1}\) bw glucose was given to all the groups and their BGLs were estimated hourly up to 2 h after glucose administration for evaluating glycemic potential.

**Study of Antidiabetic and Antilipidemic Attributes in SD Rats**

The study was carried on three groups IX, X and XI of six rats each. Group IX served as normal healthy control, group X as diabetic control and group XI was orally treated daily up to 2 weeks with a single dose of 500 mg kg\(^{-1}\) bw of ethanolic extract suspended in DW.
Control rats (group IX and X) were given vehicle (DW) only. FBG, TC, HDL cholesterol and TG levels were estimated, before and after the treatment, weekly up to 2 weeks; LDL and VLDL cholesterol levels were also calculated.

**Estimation of Urine Sugar and Body Weight in SD Rats**

Urine sugar and body weight were also assessed as additional observations in groups X and XI before and after the treatment, weekly up to 2 weeks.

**LD<sub>50</sub> Experiment**

Toxic effect of the water extract was also studied by LD<sub>50</sub> experiment. Two groups of rats of both the sexes (six animals per group, three females and three males), weighing about 180–200 g were orally administered by a single dose of 10.0 g and 15.0 g of the defatted ethanolic extract of *C. dactylon*. Then rats were observed for gross behavioral neurologic, autonomic and toxic effects continuously. Food consumption, faeces and urine were also examined at 2 h and then at 6 h intervals for 24 h.

**Statistical Analysis**

Data were statistically evaluated using one-way ANOVA, followed by a post hoc Scheffe’s test using the SPSS computer software, version 7.5. The values were considered significant when *P*<0.05.

**Results**

**Impact of Ethanolic Extract on FBG in Normoglycemic Rats**

Table 1 represents the hypoglycemic impact of graded doses of ethanolic extract of defatted *C. dactylon* on BGLs of normal healthy rats. All the three doses of 250, 500 and 750 mg kg<sup>−1</sup> bw of the extract produced a significant fall of 40.4, 47.1 and 39.4% respectively, BGL after 4 h of oral administration indicating thereby a clear hypoglycemic impact. The highest impact was marked in the animals treated with a dose of 500 mg kg<sup>−1</sup> bw. Hence this dose was identified as the most effective dose for critical evaluation of glycemic potential in case of SD models.

**Glycemic Potential of Ethanolic Extract on GTT in MD rats**

Fig. 1 depicts the effect of graded doses of 250, 500 and 750 mg kg<sup>−1</sup> bw of defatted *C. dactylon* ethanolic extract on glucose tolerance up to 2 h in MD rats. This helps in deciding the dose of 500 mg kg<sup>−1</sup> bw as the most effective dose for the study of severely diabetic models. The fall observed in BGL after 2 h of glucose administration was 10.2, 39.8 and 27.7% with the doses of 250, 500 and 750 mg kg<sup>−1</sup> bw respectively. Since, the initial fall found at 1 h was 13.2, 43.9 and 25.3% from doses 250, 500 and 750 mg kg<sup>−1</sup> bw respectively, suggesting thereby that 500 mg kg<sup>−1</sup> bw is the most effective dose for assessing the antidiabetic potential of ethanolic extract in SD animals.

![Figure 1. Hypoglycemic impact of graded doses of ethanolic extract of *C. dactylon* on glucose tolerance in mild diabetic rats. *P*<0.01 as compared to control.](image)

**Table 1. Hypoglycemic impact of graded doses of ethanolic extract of *C. dactylon* in normal rats (mean±S.D.)**

<table>
<thead>
<tr>
<th>Experimental animals</th>
<th>Treatment</th>
<th>BGLs (mg dl&lt;sup&gt;−1&lt;/sup&gt;)</th>
<th>Post-treatment levels</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Pretreatment levels</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>FBG</td>
<td>2 h</td>
</tr>
<tr>
<td>Control</td>
<td>DW</td>
<td>84.6±3.5</td>
<td>83.2±2.7</td>
</tr>
<tr>
<td>Treated</td>
<td>250 mg kg&lt;sup&gt;−1&lt;/sup&gt;</td>
<td>81.5±6.5</td>
<td>62.5±4.4</td>
</tr>
<tr>
<td>Treated</td>
<td>500 mg kg&lt;sup&gt;−1&lt;/sup&gt;</td>
<td>78.3±4.5</td>
<td>57.7±3.5</td>
</tr>
<tr>
<td>Treated</td>
<td>750 mg kg&lt;sup&gt;−1&lt;/sup&gt;</td>
<td>78.8±7.5</td>
<td>61.0±6.4</td>
</tr>
</tbody>
</table>

*P*<0.01 as compared to pretreatment level.
Antidiabetic and Antilipidemic Impact of the Most Effective Dose in SD Rats

The impact of repeated oral administration of defatted *C. dactylon* ethanolic extract on FBG and lipid profile of SD rats is shown in Table 2. FBG levels remain practically the same before and after the treatment with vehicle (water only) in case of normal control rats. Whereas, in diabetic control rats the FBG rises gradually in 2 weeks after treatment with vehicle (water only). Moreover, the 2-week treatment with the most effective dose (500 mg kg$^{-1}$ bw) of the extract decreases FBG significantly from 310.6 mg dl$^{-1}$ to 135.6 mg dl$^{-1}$ indicating thereby a fall of 56.3% in BGL. This sharp fall of 56.3% in BGL is a clear evidence of significant antidiabetic effect of defatted *C. dactylon*. A distinct lowering of TC level of 32.9% was also observed with this most effective dose after two weeks. TG level also showed a significant reduction of 48.4% in the extract-treated group. The interesting observation was an increase of 16.4% in HDL level with a decrease of 64% in LDL after treatment.

Effect of Ethanolic Extract on Urine Sugar and Body Weight in SD Rats

Table 3 and Fig. 2 reveal the impact of the most effective dose of 500 mg kg$^{-1}$ bw of defatted *C. dactylon* ethanolic extract on urine sugar levels and body weights respectively of SD rats along with normal control rats. It has been observed that the urine sugar level decrease about 75% and body weight increases about 13% after the treatment of 2 weeks.

LD$_{50}$

Experiments were carried out on normal healthy rats. The behavior of the treated rats appeared normal. No toxic effect was reported at doses up to 10 and 15 times of the effective dose of the ethanolic extract as no mortality was observed in any of these groups.

Discussion and Conclusion

The findings of this study indicate that the graded doses of 250, 500 and 750 mg kg$^{-1}$ bw of the ethanolic extract of defatted *C. dactylon* had a significant hypoglycemic effect of 40.4, 47.1 and 39.4% after 4 h of treatment in normal rats. The effect was dose-dependent up to 500 mg kg$^{-1}$ bw. However, the response decreased at higher dose of 750 mg kg$^{-1}$ bw. Such a phenomenon of less hypoglycemic response at higher doses is common in indigenous plants and has already been observed in *Momordica cymbalaua* (20), *Aegle marmelose* (21) and *Vinca rosea* (22).

The glucose tolerance test (GTT) studies of the MD animals reveal a maximum fall of 43.9% within 1 h by the extract on urine sugar levels and body weights respectively of SD rats along with normal control rats. It has been observed that the urine sugar level decrease about 75% and body weight increases about 13% after the treatment of 2 weeks.

Table 2. Impact of oral administration of the ethanolic extract of *C. dactylon* on FBG and lipid profile in SD rats (mean ± S.D.)

<table>
<thead>
<tr>
<th>Experimental animals</th>
<th>Treatment</th>
<th>Pretreatment levels</th>
<th>Post-treatment levels</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>FBG (mg dl$^{-1}$)</td>
<td>TC (mg dl$^{-1}$)</td>
</tr>
<tr>
<td>Normal (control)</td>
<td>DW</td>
<td>90.2 ± 4.5</td>
<td>280.6 ± 5.7</td>
</tr>
<tr>
<td>SD (control)</td>
<td>DW</td>
<td>310.6 ± 7.5</td>
<td>310.6 ± 7.5</td>
</tr>
<tr>
<td>SD (treated)</td>
<td>500 mg kg$^{-1}$</td>
<td>208.6 ± 5.7</td>
<td>135.6 ± 2.5*</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>HDL cholesterol (mg dl$^{-1}$)</td>
</tr>
<tr>
<td>Normal (control)</td>
<td>DW</td>
<td>57.8 ± 5.4</td>
<td>117.6 ± 6.4</td>
</tr>
<tr>
<td>SD (control)</td>
<td>DW</td>
<td>120.5 ± 3.8</td>
<td>120.5 ± 3.8</td>
</tr>
<tr>
<td>SD (treated)</td>
<td>500 mg kg$^{-1}$</td>
<td>80.5 ± 6.5*</td>
<td>80.5 ± 6.5*</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>LDL cholesterol (mg dl$^{-1}$)</td>
</tr>
<tr>
<td>Normal (control)</td>
<td>DW</td>
<td>30.7 ± 3.2</td>
<td>38.6 ± 3.5</td>
</tr>
<tr>
<td>SD (control)</td>
<td>DW</td>
<td>142.5 ± 3.2</td>
<td>142.5 ± 3.2</td>
</tr>
<tr>
<td>SD (treated)</td>
<td>500 mg kg$^{-1}$</td>
<td>146.3 ± 2.7</td>
<td>146.3 ± 2.7</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>TG (mg dl$^{-1}$)</td>
</tr>
<tr>
<td>Normal (control)</td>
<td>DW</td>
<td>85.3 ± 3.5</td>
<td>10.0 ± 5.8</td>
</tr>
<tr>
<td>SD (control)</td>
<td>DW</td>
<td>142.5 ± 3.2</td>
<td>44.3 ± 6.2</td>
</tr>
<tr>
<td>SD (treated)</td>
<td>500 mg kg$^{-1}$</td>
<td>146.3 ± 2.7</td>
<td>52.6 ± 4.2</td>
</tr>
</tbody>
</table>

*P<0.001 as compared to pretreatment levels.

Table 3. Impact of the most effective dose of *C. dactylon* ethanolic extract on urine sugar in SD rats (mean ± S.D.)

<table>
<thead>
<tr>
<th>Experimental animals</th>
<th>Treatment</th>
<th>Pretreatment levels</th>
<th>Post-treatment levels</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normal (control)</td>
<td>DW</td>
<td>Nil</td>
<td>Nil</td>
</tr>
<tr>
<td>SD (control)</td>
<td>DW</td>
<td>+++++</td>
<td>+++++</td>
</tr>
<tr>
<td>SD (treated)</td>
<td>500 mg kg$^{-1}$</td>
<td>++++</td>
<td>++++</td>
</tr>
</tbody>
</table>

*P<0.001 as compared with pretreatment.

Figure 2. Impact of the most effective dose of *C. dactylon* ethanolic extract on body weight in SD rats. *P<0.001 as compared with pretreatment.
dose of 500 mg kg$^{-1}$ bw whereas, the doses of 250 mg kg$^{-1}$ bw and 750 mg kg$^{-1}$ bw produced a fall of about 13.2 and 25.3% only in 1 h in BGL. Since this maximum fall was sustained by the dose of 500 mg kg$^{-1}$ even after 2 h of glucose administration in comparison to other doses, therefore, the suggested effective dose for the study of SD animals was found to be 500 mg kg$^{-1}$ bw. The results of GTT of normoglycemic animals observed were on similar pattern verifying thereby the dose of 500 mg kg$^{-1}$ as the most effective dose and therefore a dose of choice for the study of severe cases. This suggested and verified effective dose showed a marked decrease in FBG level of 56.3% in SD animal after 2 weeks treatment, among all other doses used.

It has been observed mostly that hyperlipidemia has been reported to accompany hyperglycemia states (23) and the most common lipid abnormality observed is hypertriglyceridemia. The marked hyperlipidemia that characterizes the STZ-diabetic rats seems to be a consequence of uninhibited action of lipolytic hormones on adipose tissue. Since insulin inhibits adipose tissue hormone sensitive lipase and reduces lipolysis, C. dactylon may mimic insulin action. The dose of 500 mg kg$^{-1}$ bw of the ethanolic extract not only lowered the TC, TG and LDL levels by 32.9, 48.4 and 64% but also enhanced the level of cardio protective HDL cholesterol by 16.4% after 2 weeks of treatment. Several studies showed that an increase in HDL cholesterol is associated with a decrease in coronary risk and most of the drugs that decrease TC also decrease HDL cholesterol (24). It is important to note that in the present study the ethanolic extract not only decreased the TC but also increased the HDL cholesterol significantly after 2 weeks treatment as an additional advantage over the existing drugs. Since diabetes is associated with coronary complications (25), which is the major cause of morbidity and deaths in diabetic subjects (26,27) due to high levels of TC and more importantly LDL cholesterol, intake of ethanolic extract of defatted C. dactylon will therefore help in reducing the incidence of coronary events.

It has been reported recently that TG level is independently related to coronary heart disease (28,29) and most of the antihypercholesterolemic drugs do not decrease TG levels (30,31). This study clearly shows that the most effective dose of 500 mg kg$^{-1}$ bw of the ethanolic extract decreases TG level also by 48.8% after 2 weeks treatment.

From this study we can conclusively state that defatted C. dactylon ethanolic extract has significant hypoglycemic as well as antidiabetic effects on BGLs of normal, mild and severely diabetic models. A substantial improvement on hyperlipidemia due to diabetes was also observed. Its unique effect of increasing HDL level about 16.4% has additional advantage of reducing coronary risk. Further characterizations of active components in C. dactylon are warranted and studies are in progress to isolate, identify and characterize active components. These results suggest that the product of C. dactylon may provide a new therapeutic avenue against diabetes and diabetes-related complications—a global burden. Moreover, natural health products of vegetable origin were clearly indicated as a promising avenue for the prevention of chronic diseases (32), as raised notably by a panel of experts that convened in Montreal in 2004 (33). Wide-spread research is currently taking place in China, India and other countries too in order to explore new traditional Chinese, Indian and Western medicines that will prevent and treat diabetes mellitus and its chronic complications (34–36).

**Acknowledgement**

The authors are thankful to NMPB, Ministry of Health and Family Welfare Government of India, India for providing the financial assistance.

**References**


Received September 29, 2006; accepted March 8, 2007